Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on SCMP. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a strong sell rating to a hold rating in a report on Tuesday, July 4th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, June 23rd. Mizuho reiterated a buy rating and set a $14.00 price objective on shares of Sucampo Pharmaceuticals in a report on Tuesday, April 4th. Finally, Jefferies Group LLC dropped their price objective on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a hold rating on the stock in a report on Thursday, May 4th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $17.63.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 0.48% during trading on Wednesday, reaching $10.40. The company’s stock had a trading volume of 469,212 shares. The company’s market cap is $480.42 million. The stock’s 50-day moving average is $10.58 and its 200 day moving average is $10.73. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. During the same quarter in the prior year, the business earned $0.24 earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities analysts forecast that Sucampo Pharmaceuticals will post $1.02 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Maxim Group Reiterates “$23.00” Price Target for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/05/maxim-group-reiterates-23-00-price-target-for-sucampo-pharmaceuticals-inc-nasdaqscmp.html.

Large investors have recently bought and sold shares of the company. LSV Asset Management increased its stake in Sucampo Pharmaceuticals by 11.4% in the first quarter. LSV Asset Management now owns 2,346,418 shares of the biopharmaceutical company’s stock valued at $25,810,000 after buying an additional 239,200 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock valued at $21,130,000 after buying an additional 103,986 shares during the last quarter. Vanguard Group Inc. increased its stake in Sucampo Pharmaceuticals by 48.9% in the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after buying an additional 478,226 shares during the last quarter. NEA Management Company LLC acquired a new stake in Sucampo Pharmaceuticals during the second quarter valued at approximately $13,214,000. Finally, Royce & Associates LP increased its stake in Sucampo Pharmaceuticals by 24.6% in the first quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock valued at $10,714,000 after buying an additional 192,000 shares during the last quarter. 55.82% of the stock is owned by institutional investors.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.